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In  previous  experiments we have  shown  that  multiple paralytic 
doses of poliomyelitis virus, when mixed with very small amounts of 
crystalline vitamin C  (l-ascorbic acid), are rendered non-infectious as 
determined by  intracerebral injection of  such  mixtures  into  rhesus 
monkeys (1).  What made this phenomenon particularly interesting 
was the existence of a rather narrow quantitative range within which 
vitamin C seemed to be most effective, the optimal doses lying be- 
tween 10 rag. and 1 rag.  A similar zone was previously described by 
us in the inactivation of diphtheria toxin by vitamin C  (2). 
These observations naturally raised the  question whether or not 
the injection of vitamin C into monkeys suffering from experimental 
poliomyelitis might be followed by any alteration in the severity of 
the infection.  The experimental trial of this idea has led to encourag- 
ing results which have already been published in preliminary form  (3). 
To summarize briefly: It was found that a small group of 4 monkeys 
which had received daily injections of 5 rag. of vitamin C, beginning 
with the day of the infection, survived without showing any symp- 
toms of paralysis.  In another group of 16 animals which had been 
treated with somewhat larger doses  (50  to  100  rag.),  11  developed 
typical paralysis, 3 showed an atypical form of the disease (onset of 
paralysis delayed over 2 weeks), and 2 remained free from any par- 
alytic symptoms.  Finally, another  group of  9  animals  which had 
received very large doses of vitamin C (100 to 700 rag.) all succumbed 
to  the disease in  a  typical manner.  10  control monkeys, injected 
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intracerebrally like the treated animals with 0.1 cc. of a  10 per cent 
virus  suspension, but  left without treatment,  all  developed typical 
paralysis within from 6 to  11  days. 
The limited data which formed the basis of this preliminary report 
naturally precluded the drawing of any definite conclusions.  They 
seemed to  suggest,  however, that vitamin  C  when administered in 
the proper dose may possess  distinct therapeutic properties in experi- 
mental  poliomyelitis.  It  became  necessary,  therefore,  to  continue 
this  line of  work  and  to  amplify our  original observations  with  a 
larger number of tests.  At the same  time, it  seemed advisable to 
investigate whether prophylaxis with vitamin C afforded any protec- 
tion against  subsequent  inoculation with poliomyelitis virus.  It is 
the object of this paper  to present in detail the new experimental 
data obtained in the continued study of this problem, together with 
those reported previously in preliminary form. 
EEPEI~NTAL  WORK 
The observations reported in this  paper bear on a total  of nearly 
I00 rhesus monkeys treated  in various  ways with vitamin C before  or 
after intracerebral infection with poliomyelitis virus and about half 
that number of control animals which accompanied these tests.  For 
the  sake  of clarity in presentation,  these  data  will be  arranged in 
three  sections: the  first  dealing with  therapeutic  experiments;  the 
second with prophylactic experiments;  and the third describing ex- 
perimental work of somewhat different nature, but generally related 
to the main problem under investigation. 
1.  Therapeutic Experiments 
Rhesus monkeys weighing from 2000 to 3000 gm. were inoculated intracerebraUy 
with three different amounts of poliomyelitis virus (Aycock strain), i.e.,  0.1  cc., 
0.05 cc. and 0.01  cc. of a  10 per cent virus suspension.  These animals were then 
treated for a  period of 2 weeks with daily injections of vitamin C I of various 
dosage.  11  different series were run.  In 9 of these, treatment  was  uniformly 
begun on the day of inoculation; in the last 2 series, the initial injection was de- 
layed in some animals until 48 or 72 hours, respectively, after the day of infection. 
1 We are greatly indebted to Merck and Co., Rahway, New Jersey, for placing 
at our disposal a  generous supply of cebione, their crystalline natural vitamin C 
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The doses of vitamin C covered a range from 700 rag. to 5 rag. and were mostly 
administered by the subcutaneous route.  Control monkeys, which were infected 
intracerebrally  at  the same  time with  the corresponding dose of virus, accom- 
panied each series.  With the larger doses of virus we have satisfied ourselves, 
as a  rule,  with 2 controls for each series; when smaller doses of virus were em- 
ployed, the number of controls was usually increased,  in some cases to approx- 
imately equal the number of treated animals.  All animals were carefully observed 
for 1 month and symptoms noted.  In case of paralysis or death, an autopsy was 
made and the diagnosis confirmed by histological examination of the spinal cord. 
Surviving animals were reinoculated at the end of 1 month.  The protocols of 
these individual series are given in Table I.  A  summary in which all animals 
are grouped according to the size of the infecting dose will be found in Table II, 
while Table III lists the results obtained in accordance with the amount of vitamin 
C injected. 
A  study of Table III, which considers only the effect of various dosages of 
vitamin  C,  without regard  for the varying severity of the infection,  leaves no 
doubt that large doses of vitamin C, i.e.,  amounts ranging from 700 to 100 rag., 
had no influence whatsoever on the course of the disease.  Thus, we find that all 
10 monkeys which had been treated with such excessive  amounts succumbed to 
the infection.  On the other hand, animals treated with intermediate  doses  (50 
to 10 rag.) occasionally remained free from paralytic symptoms or else developed 
paralysis only after prolonged incubation periods.  This is illustrated by the fact 
that of a total of 19 monkeys in this category, 3 escaped the disease entirely and 3 
came down with  paralysis between  15  and  21  days, the  remaining  13  animals 
developing typical poliomyelitis.  More favorable results, however, were obtained 
with monkeys which had received 5 rag. of vitamin C.  To wit  s of a total of 33 
animals treated with this particular dose, not less than 16 survived without show- 
ing any evidence of paralysis, 2 developed the disease after  15 and  16 days, re- 
spectively, while the remainder, i.e., 15, succumbed to typical poliomyelitis. 
These results  must be evaluated,  of course, in the light of the incidence of 
paralysis among the controls.  If we consider the controls first en bloc, irrespective 
of differences in the size of the infecting dose, it appears that of a  total of 38 
control monkeys, 36 succumbed to the disease (34 developing typical poliomyelitis 
within less than 2 weeks incubation period and 2 after  17 and  16 days, respec- 
tively), while 2 failed to show any manifest symptoms of paralysis. 
Directly comparable data may be obtained from a study of Table II in which 
all animals, treated and untreated, are listed according to the size of the infecting 
dose.  It will be seen that of a total of 34 vitamin C-treated animals which had 
been infected with 0.1  ee.  of virus,  25  developed typical and 3  atypical polio- 
myelitis, while 6  remained free from any paralytic symptoms.  All 10 controls 
infected with the same dose of virus came down with typical poliomyelitis.  Of 
6 treated animals infected with half the amount of virus, i.e.,  0.05 cc., 1 escaped 
the disease,  2 developed atypical and 3 typical poliomyelitis.  Again, all 7 con- 
trois infected with the same dose of virus developed the disease, 6 typically and TABLE  I 
Vitamin  C  Therapy  in  Experimental  Poliomyelitis 
¢c.  rag. 
Series 1  083  0.1  5013 Complete paralysis, 14 days 
070  .... 
Series2  Q28 
Q29 
Q3O 
Q31 
Q32 
Q33 
Q34 
Controls 
"  200  8  " 
"  700  ....  "  " 
"  5013  "  "  5  " 
"  200  "  "  "  " 
"  50  Partial  paralysis, I 1  " 
....  Complete paralysis,  5  '" 
069 Complete paralysis,  8  days 
D90  ........ 
Q13 Complete paralysis,  8  days 
!Q26 Partial  paralysis,  9  " 
Series3  Q48  "  500  ....  7  " 
Q47  "  100  ........ 
Q46  "  50  ....  10  " 
Q49  ......  "  8  " 
QS0  "  "  "  "  11  " 
Q53  ........  21  " 
Q51  "  25  ....  10  " 
Q52  ........  7  " 
Q45  ....  No paralysis 
Q78  "  "  Complete paralysis, 16 days 
Series 4  R13  "  "  "  "  11  " 
R15  "  10  "  "  8  " 
R16  "  "  "  "  15  " 
R17  "  5  No paralysis 
R18  "  "  .... 
Series 5  R19  "  25  .... 
R20  "  10  Complete paralysis, 11 days 
R21  "  .....  '  "  " 
R22  "  5  No paralysis 
R23  "  "  "  " 
ieries 6  $21  " 
$25  " 
$48  " 
R51  " 
R53  " 
cc 
"  Complete paralysis,  7 days 
"  Partial  paralysis,  8  " 
Q54 Complete paralysis, 11 days 
(255  ........ 
Qg0  ....  9  " 
Q76  ....  11  " 
!R12 Complete paralysis,  7  days 
R25 Complete paralysis,  7 days 
R37  "  "  .... 
S18  Partial  paralysis,  8  days 
$20  Complete paralysis,  6  " 
R49  ....  14  " 
R50  "  "  8  " 
R52  "  "  "  " 
R60  "  "  6  " 
R63  "  "  9  " 
R3  "  "  5  " 
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Series 7 
Series 8 
Series 9 
Series 10 
Series 11 
R89 
$5 
L~ 
¢¢.  rag, 
0.051 
t, 
tt 
4, 
$78  "  25 
$75  " 
$88  "  " 
$89  "  " 
Result 
5  Complete paralysis,  8 days 
"  "  "  9  " 
$90  0.01 1013 
$91  "  5C 
$79  "  25  No paralysis 
$76  "  5  .... 
Complete paralysis,  9 days 
"  "  16  " 
No paralysis 
Partial  paralysis, 15 days 
Complete paralysis,  9  " 
"  "  10  " 
$95 
$96 
$97 
$98" 
$99" 
S100* 
"  "  Complete paralysis,  8 days 
"  "  No paralysis 
"  "  Complete paralysis,  9 days 
"  "  "  "  9  " 
T18  "  "  Complete paralysis,  9 days 
T19  "  "  "  "  8  " 
T20  ....  No paralysis 
T21  "  "  "  " 
T22  "  "  "  " 
T23  "  "  "  " 
T25"*  "  "  "  " 
T26"*  "  "  "  " 
T27"*  "  "  "  " 
T28"*  "  "  Complete paralysis,  9 days 
T29'*  "  "  No paralysis 
T30**  "  "  Complete paralysis,  9 days 
Con~o~ 
R95 Complete paralysis  8 days 
R91  "  "  7  " 
R98  "  "  11  " 
R54  "  "  17  " 
$67  ....  12  " 
$68  ....  "  " 
$94  ....  11  " 
369  "  "  7 days 
$70  "  "  "  " 
T1  Complete paralysis, 16 days 
T2  "  "  7  " 
T3  "  "  8  " 
T5  "  "  7  " 
T6  "  "  9  " 
T7  No paralysis 
T9  Complete paralysis,  7 days 
T15 No paralysis 
T16 Complete paralysis,  9 days 
T17  "  "  "  " 
All  treated  animals  received  daily  injections  of  vitamin  C  of  the  indicated 
dosage for a  period  of 2  weeks,  or until the onset of paralysis.  Treatment  was 
begun  on  the  day  of infection,  excepting animals  marked  ** in  which  the first 
injection  was not  given until 48 hours after  infection,  and  animals marked  *  in 
which the first injection was not given until 72 hours after infection. 132  VITAMIN  C  THERAPY  IN POLIOMYELITIS 
1 after 17 days.  More significant results were obtained with monkeys which had 
been infected with the smallest dose of virus.  Of 22 vitamin C-treated animals, 
TABLE  II 
Effect of Various Doses of Vitamin C in Experimental  Poliomyelitis  with Respect 
to Variation~ in the Size of the Infecting Dose of Virus 
Treated Animals 
Dose of virus 
0.1 
0.05 
0.01 
Dosage of 
vitamin C 
mg. 
700-100 
50-  10 
5 
700-100 
50- 10 
5 
700-100 
50- 10 
5 
Number 
of monkeys 
9 
16 
9 
34 
1 
2 
19 
22 
62 
No paralysis 
0 
0 
1 
0 
1 
11 
12 
19 
Atypical 
paralysis 
Typical 
paralysis 
9 
11 
5 
25 
10 
38 
Untreated Control Animals 
Dose of virus 
0.1 
0.05 
0.01 
Number of monkeys 
19 
7 
12 
No paralysis  Atypical paralysis  Typical paralysis 
19 
6 
9 
38  2  2  34 
Atypical paralysis =  onset of paralysis later than 2 weeks following infection. 
Typical paralysis  =  onset of paralysis within 2 weeks following infection. 
which had been infected with 0.01 cc. of virus, 12 remained free from any paralysis, 
while 10 came down  with typical poliomyelitis.  In contrast herewith, we find 
among 12 control animals infected with the same amount of virus, 10 which suc- CLAUS  W.  J'UNGEBLUT  133 
cumbed to the disease (9 typically and 1 after 16 days) and only 2 that failed to 
show any paralysis. 
While it can readily be appreciated that the chances for a therapeutic effect 
must improve with a reduction in the size of the infecting dose, we believe that 
even animals infected with the larger amounts of virus show evidence of having 
benefited from the treatment, provided the dosage of vitamin C is kept within 
optimal limits.  Thus, we have among a group of 14 monkeys  infected with 0.1 cc. 
or 0.05 cc. of virus, which were treated with 5 mg. of vitamin C beginning with 
the day of the inoculation, no less than 5 survivors without paralysis, whereas 
all 26 controls infected with the same amounts of virus developed the disease. 
In a similar way, considerably better  figures are obtained for monkeys  which 
had been infected with the smallest amount of virus, i.e.,  0.01 cc., if we exclude 
animals treated with the larger doses and consider only those which had received 
5 rag. of vitamin C.  It will be found that of 10 such animals, in which treatment 
was begun on the day of infection, 7 escaped the disease.  Even under adverse 
conditions, when treatment  was delayed until  48 or  72  hours after  infection, 
this method of treatment has apparently saved 4 of 9 monkeys from paralysis. 
When left without treatment, only 2 of 12 controls inoculated with the same dose 
of virus, i.e., 0.01 cc., remained  free from paralysis. 
Whether the data are taken as a whole or are interpreted according 
to gradations in the size of the infecting dose, it appears that treat- 
ment with 5 rag. of vitamin C has reduced the incidence of paralysis 
roughly by  one-half  as  compared  with  untreated  controls.  Thus, 
we have among a  total of 33 monkeys which were treated with this 
dose,  51.5  per  cent  (17)  that  developed paralysis against 94.7  per 
cent  (36) among  a  total  of  38  controls.  Similarly,  among  19  of 
these treated animals, which had been infected with 0.01  cc. of virus, 
the incidence of paralysis stands at 42.1  per  cent  (8)  as  compared 
with  83.3 per  cent  (10)  among  12  corresponding  controls.  While 
the above figures would seem to be definitely significant, we do not 
wish to overemphasize their importance, because of the limited num- 
ber of controls inoculated with the smallest dose of virus.  Moreover, 
a study of the individual series makes it clear that distinct limitations 
are set in the extent and regularity of the therapeutic effect by experi- 
mental factors that  are beyond control.  All  attempts  to  improve 
upon these results by other modifications in the form of treatment-- 
i.e.,  further reduction in the dosage of ascorbic acid to I rag. and less; 
gradual increases from day to day; intraspinal injection of this sub- 
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of cortin--have been mthout avail.  It is possible that a greater per- 
centage of treated animals might survive after intranasal instillation 
of the virus, but this method of infection would automatically increase 
the number  of  survivors  among  the  controls  without  necessarily 
strengthening the statistical significance of the results. 
It is a  common experience that  the infectivity of passage strains 
of virus may fluctuate considerably from time to time (4).  But even 
at  times of maximum virulence an occasional monkey may survive 
without paralysis following intracerebral injection of an  amount of 
virus which is capable of producing prostrating paralysis or death in 
all other animals in  that particular series.  Obviously, such irregu- 
larities  occur  more  frequently with  the  smaller  doses  of  virus  al- 
TABLE  III 
Comparison of the Effect of Various Dosages of Vitamin C 
Dosage of vitamin C 
mg. 
700-100 
SO-- 10 
5 
Number of animals 
10 
19 
33 
62 
No paralysis 
0 
3 
16 
19 
Atypical paralysis  Typical paralysis 
10 
13 
15 
38 
Explanation for atypical and typical paralysis see in Table II. 
though  they are not  at  all uncommon with  animals  given massive 
doses.  As  regards  the  particular  strain  of virus  employed in  this 
work, we have observed over a period of about 7 years among several 
hundred control animals between 5 and 10 per cent that have failed 
to  develop  paralysis  upon  intracerebral  injection  of  doses  of  virus 
ranging from i cc. to 0.01 co. of a 10 per cent virus suspension.  More- 
over, when paralysis occurred, it was usually so severe that the animal 
became  completely prostrated.  Repeated  titrations  of  our  strain 
during  the  year when  these  experiments were  under  way indicate 
that the minimum paralytic dose of virus at that time was well below 
0.01  cc.  (see  Table  IV).  The  reasons  for  the  occasional  survival 
without  paralysis  of  control  animals  injected  intracerebrally  with 
multiples of the minimum paralytic dose of virus are not clear.  They CLAUS W.  ~UNGEBLUT  135 
are just as obscure as the more pronounced variations in the suscep- 
tibility of monkeys observed with methods of infection other than 
intracerebral injection of the virus (intranasal,  subcutaneous, intra- 
dermal)  or  the  widespread  insusceptibility  among  other  animal 
species, including man.  Suffice it  to  say  that  technical errors  can 
usually  be  eliminated and  that  such  animals  evidently possess  an 
exceptionally high  degree  of  natural  resistance.  This  is  also  sug- 
gested by the fact that the resistant animals often refuse to develop 
TABLE  IV 
Titrations of Infectivity of A ycock Strain of Poliomyelitis Virus during 1935 (Intra- 
cerebral Injection) 
Monkey  10% virus suspension  Result 
N88 
N84 
N85 
N86 
N87 
NIO0 
O1 
02 
03 
020 
021 
022 
023 
0.1 
cC 
0.05 
cc 
c~ 
0.01 
0.005 
0.001 
0.1 
~c 
0.01 
Complete paralysis, 7 days 
cc  c¢  5  cc 
O 
¢c  cc  cc  cC 
cc  c~  c¢  ~ 
Questionable paralysis 
Complete paralysis  7 days 
~  ¢~  9  cc 
Partial paralysis,  17  " 
the  disease  on reinfection.  In  order  to  determine to  what  extent 
such refractory animals may have been present among our treated 
animals and controls, we have reinoculated all surviving animals at 
the end of the 1 month period of observation. 
It appears from Table V that of 15 treated animals which had es- 
caped paralysis and which had not died of intercurrent disease before 
1 month had elapsed, all but 1  developed typical poliomyelitis upon 
intracerebral reinjection with 0.1  cc. or 0.01  cc. of virus.  Of the 2 
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the other developed typical poliomyelitis.  This result, in our opinion, 
suggests that  practically  all of our treated  animals  were potentially 
susceptible to the virus and that, if any escaped paralysis during  the 
first infection,  the escape may well have been due to the vitamin  C 
treatment.  It also serves to illustrate that a non-paralyzing infection 
TABLE  V 
Reinfection  of  Surviving  Monkeys,  Treated  and  Untreated 
R17 
R19 
R22 
R23: 
S76 
$79 
$96 
$97 
T7 
T20 
T21 
T23 
T25 
T26 
T27 
T29 
T15 
Dose 
Type of anlma]  of  Remit 
virus 
CC. 
Treated  D. 1  Complete paralysis,  7 days 
"  "  Partial  paralysis, l!  " 
"  "  Complete paralysis,  6  " 
"  "  "  "  9  " 
~L 
Treated  0.01  Complete paralysis, 10 days 
"  "  "  "  11  " 
Untreated  "  No paralysis 
Treated  "  Complete paralysis,  5 days 
"  "  Partial  paralysis, 11  " 
"  "  Complete paralysis,  7  " 
"  "  Partial  paralysis, 11  " 
"  "  Complete paralysis,  9  " 
"  "  No paralysis 
"  "  Partial paralysis,  11 days 
Untreated  "  Complete paralysis,  9  " 
Controls 
S18  Partial paralysis,  8 days 
$20  Complete paralysis,  6  " 
R3  "  "  5  " 
R49  "  "  14  " 
R50  "  "  8  " 
R52  ......  " 
R60  "  "  6  " 
R63  "  "  9  " 
T12 Complete paralysis, 8 days 
T31 Complete paralysis, 8 days 
with poliomyelitis virus rarely if ever is followed by immunity in the 
monkey,  a  fact  which  we  have  amply  demonstrated  in  a  previous 
paper  (5). 
2. Prophylactic Experiments 
In view of the fact that therapeutic  injection of vitamin  C in proper doses 
seemed to have a favorable effect on the course of the established disease, we have CLAUS W.  JUNGEBLUT  137 
next investigated  whether a prophylactic administration  of this substance afforded 
any protection against subsequent  inoculation.  To achieve this end, two different 
methods were followed.  A total of 16 monkeys were prepared by daily injections 
of vitamin C of various  dosage (25 rag. to 500 mg.) for a period of 1 or 2 weeks 
and then injected intracerebrally  with 0.1 cc. of virus; at the same time, 8 control 
animals were injected  intracerebrally  with the identical  dose of virus.  A second 
group of 10 monkeys were given  daily,  for a period  of 2 weeks, approximately 
1S0 rag.  of vitamin  C in  their food.  This amount represents  merely  a  rough 
estimate since the eating habits of monkeys make it impossible to obtain control 
over the  amount actually ingested.  At the  end  of the  2 weeks period,  these 
monkeys were injected  intracerebrally  with 0.01 cc. of virus; 7 control animals 
injected with the same dose of virus accompanying this test.  The results of these 
two experiments  appear in Table VI. 
As may be seen from Table VI, we have in the first experiment only one monkey 
which  survived without paralysis,  the remaining  15 animals  all  developing  the 
disease like  the corresponding  8 controls.  In the second  experiment  (feeding) 
we find among 10 prepared animals  again one survivor without paralysis and 2 
additional  animals that developed the disease after prolonged incubation periods 
(18 and 19 days, respectively).  This result, however, is offset by the fact that of 
7 corresponding control animals, one survived without paralysis  and another one 
developed the disease only on the 15th day.  We conclude, therefore,  under the 
conditions of the test, that prophylaxis with vitamin C was without any significant 
effect on the course of subsequent  infection with poliomyelitis virus. 
3.  Miscellaneous Experiments 
In this  section  we  have  grouped together  some miscellaneous  ex- 
periments which are not strictly concerned with vitamin C prophylaxis 
or  therapy  but  which  are  nevertheless  intimately  related  to  the 
main problem under investigation. 
The first question we were interested  in was whether the apparent therapeutic 
effect of vitamin C could be ascribed  to any direct action of the ascorbic acid on 
the virus.  An answer to this question could be found by determining  whether or 
not vitamin C, when injected intracerebrally  in a single dose at the site of infection, 
was capable of preventing the disease.  Accordingly, a group of 4 monkeys was 
injected intracerebraUy with 5 mg. and 10 rag. of vitamin C, respectively.  Mter 
2 hours had elapsed,  a dose of 0.05 cc. of virus  was injected  through the same 
puncture in the skull into the brain.  Another group of 4 monkeys was treated 
in the same way, except that here the virus injection preceded the injection of the 
drug by 2 hours.  All 8 experimental animals developed paralysis as did all of the 
9 controls which had been infected with the same dose of virus.  It follows from 
this experiment  that vitamin C, although seemingly  virucidal  in vitro, fails  to 
accomplish a local sterilizing effect in the central nervous system, under the con- 
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Experiments were next carried out to determine whether the addi- 
tion of vitamin  C  to normal,  non-neutralizing  monkey serum would 
render  the  serum  virucidal.  While  such  "vitaminized"  sera  have 
occasionally  brought  .about  neutralization  of  the  virus  in  mixture 
tests, irregular and confusing results were obtained on repetition with 
different doses of vitamin C.  This makes it difficult to delimit clearly 
a neutralizing zone that might be compared with the range of natural 
vitamin  C  content of serum.  Again, we have been unable up to the 
present to determine that the serum of normal monkeys, which had 
received large doses of vitamin  C, acquires the property of neutraliz- 
ing the virus as the result of such preparation.  It seems as if inactiva- 
tion of the virus by vitamin C in the presence of serum is by no means 
as regular and clear cut a phenomenon as its inactivation by the same 
substance in aqueous solution.  This phase of the work is being con- 
tinued. 
We should finally mention in passing a short set of experiments designed to 
test the specificity of the apparent therapeutic effect of vitamin C.  This couldbest 
be done by determining whether the use of other vitamins had any beneficial effect 
on the course of the disease.  4 monkeys were injected intracerebraUy with 0.1 cc. 
of virus.  2 were given daily injections of 100 rag. of vitamin A (in the form of 
crystalline carotene), the 2 other animals receiving instead daily injections of 1 gin. 
of vitamin B (in the form of powdered yeast).  All 4 monkeys developed typical 
poliomyelitis as did 4 accompanying  controls.  Apparently therefore, under the con- 
ditions of our test, vitamins A and B were without therapeutic effect in experi- 
mental poliomyelitis. 
DISCUSSION 
For a number of years we have contended that success in the control 
of  infantile  paralysis  must  depend upon  the  accumulation  of  more 
precise  knowledge  regarding  the  mechanism  of  natural  protection 
against  this disease  (6).  Once it is clearly understood why the ma- 
jority of children  and  an even greater  number  of  adults  fail  to de- 
velop paralysis upon  exposure to  the  infectious agent,  or--and  this 
is expressing the same thought perhaps more trenchantly--why  cer- 
tain  exceptional  children  are so highly susceptible that  first contact 
with  the  virus  leads  to  invasion  of  the  central  nervous  sytem,  it 
might  be possible to  apply  the  same principles  to  the  therapy  and 
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Protection in poliomyelitis occurs in the form of two basic types of 
resistance which we believe to differ fundamentally from each other. 
The first is found in the solid immunity which is acquired after re- 
covery from a paralyzing attack, a form of protection essentially due 
to a  refractory state of the nerve tissue, which may or may not be 
accompanied by  the presence of  circulating antibodies.  This  pro- 
tection, specific in character, nearly absolute in intensity and perma- 
nent in duration, in our opinion follows only after contact of the sus- 
ceptible nerve cells with living virus, its development depending upon 
the production of actual lesions.  The second, and as it seems to us 
more important type of protection, is represented by the resistance 
of naturally insusceptible individuals to this extraordinarily selective 
disease.  Such resistance is expressed by complete insusceptibility of 
certain  animal  species,  by  the  varying  susceptibility  of  different 
human races, or in individual variations within the same race.  The 
extensity and intensity of this non-specific resistance is  characteris- 
tically  conditioned  by  innate  and  environmental factors,  such  as 
heredity, sex, age, season and locality. 
Two opposing theories hkve been invoked to explain the mechanism 
of this natural resistance, particularly in the case of man.  The first, 
supported  mainly by  indirect epidemiological deduction, interprets 
the phenomenon as  due to well nigh universal immunizing contact 
with the virus, progressing with the advance of age.  It is assumed 
to be brought about by strictly subclinical immunization or by mani- 
fest  but  abortive  attacks.  According to  the  second theory, polio- 
myelitis is essentially a developmental disorder of youth, and protec- 
tion against the disease is chiefly due to physiological factors.  The 
fundamental difference in these two concepts is perhaps more clearly 
illustrated by their implications.  The immunization theory regards 
all human beings as primarily susceptible and attributes protection 
exclusively to acquired specific immunity; hence, cases must develop 
either in individuals that have escaped such immunizing contact or 
else in persons that are less immunizable.  The so called maturation 
theory, on the other hand, holds that man, under natural conditions 
of infection, is normally insusceptible and  can  carry the virus with 
impunity.  Production  of  the  disease  which  occurs  only  in  com- 
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must  therefore  be  brought  about  by  some  transient  physiological 
abnormality or deficiency, hormonal or nutritional in character. 
It has been our conviction that the known facts agree better with 
the theory of physiological resistance than with the assumption of an 
almost universal latent  immunization.  The  reasons  for  this  belief 
are founded briefly (a) on the inability to demonstrate clearly a process 
of subclinical immunization in  either  the monkey or man;  (b)  the 
lack of evidence that virucidal function of the serum and bodily re- 
sistance to infection in man or animals are necessarily correlated with 
previous exposure to the virus, and (c) direct experimental data which 
indicate that poliocidal substances found in normal human or animal 
tissues, serum or other body fluids are probably not of antibody char- 
acter but resemble agents of vitamin-like or hormonal nature (7). 
We have reviewed this controversy since on its determination de- 
pends any reasonable approach to treatment and prevention of polio- 
myelitis.  Specific means of therapy through convalescent or immune 
serum having failed, experimentally as well as clinically, attention has 
concentrated lately on specific prophylaxis.  Two methods of active 
immunization have been proposed, one involving the use of killed, the 
other the use of live virus.  As might have been predicted, both have 
been  given  up.  It  appears  that  immunization with  killed  virus, 
although  engendering antibody  formation,  falls  short  of  providing 
cellular  protection  which  is  the  prominent  characteristic  of  true 
immunity in poliomyelitis (8).  The use of live virus, on the other 
hand, even though attenuated, involves too great  a  risk in human 
beings.  The  chances,  moreover,  are  that  naturally  insusceptible 
individuals will destroy the virus without deriving any more benefit 
from it than ]~rom  casual contact, and that susceptible individuals may 
develop  the  disease  (9).  It  is  inevitable,  therefore,  that  logical 
prophylaxis and treatment of infantile paralysis must center around 
attempts to imitate the mechanism of natural defense by enhancing 
normally  functioning  non-specific  agencies,  or  by  correcting  the 
existing physiological deficiency by providing the missing nutritional 
or  hormonal  elements  in  adequate  amounts  and  proportions.  It 
seems from the results of our work that this might possibly be accom- 
plished by supplying the infected individual with an optimum amount 
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The assumption that vitamin C is an important factor,of non-spe- 
cific defense in infantile paralysis is suggested not only by the fact that 
ascorbic acid behaves like an unusually potent virucidal agent in vitro, 
but is also supported by certain other considerations.  Thus, vitamin 
C is found in all normal body fluids which possess poliocidal properties 
(serum, tears, placenta, pregnancy urine, adrenal extracts).  Next to 
the adrenal glands, it is present most abundantly in the central nerv- 
ous system (10).  During pregnancy and lactation its concentration 
in  the  body seems to  be sharply increased, the  placenta and milk 
representing the principal sources of exogenous supply for the embryo 
and newborn during prenatal and postnatal life (11).  It is asst/med 
by some investigators (12)  that infants during the first few months 
after birth  are  capable of  synthesizing this substance, like the rat, 
but that this capacity is lost or greatly diminished at the time of the 
physiological involution of the adrenal cortex, which occurs towards 
the end of the 1st year.  These two points in the development of the 
child  coincide  characteristically  with  the  maxima  and  minima  of 
susceptibility  to  poliomyelitis.  ~  Little  is  known  about  the  actual 
demand for vitamin C, the extent of its assimilation and rate of excre- 
tion in health and disease and under varying environmental conditions. 
Suffice it to say, that although the precise relationship between the 
glands of internal secretion and vitamin metabolism is as yet not well 
understood, it is becoming increasingly clear that their operation is 
intimately interlocked since fluctuations in the supply of the. latter 
lead  to  dysfunction  of  the  former.  Even  though  fully  developed 
C avitaminosis,  long recognized as the classical cause of scurvy, is but 
rarely observed today under normal living conditions, recent experi- 
ence has  shown that  examples of minor deficiencies,  or'C hypovita- 
minoses, are by no means infrequent (13).  The so called prescorbutic 
state,  for  instance,  is  not  uncommonly found  in  actively growing 
children whose vitamin C requirements are known to exceed greatly 
those of adults for the maintenance of an adequate level.  That this 
level may change considerably from time to time, possibly through 
changes in the thyroid gland  (14),  is suggested by seasonal fluctua- 
tions in the content of vitamin C in cows' milk (15) and in the rate of 
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its excretion in man through the urine, as determined by tolerance 
tests (16).  A serious disturbance of vitamin C storage is furthermore 
indicated during poliomyelitic infection by the occurrence of severe 
lesions in the adrenal gland (17) and an actual loss of reducing sub- 
stances in this organ (18).8  To this must be added the pathognomonic 
frequency in infantile paralysis of gastrointestinal disorders--so often 
encountered in children suffering from a low grade C hypovitaminosis 
--which in turn lead to a further impoverishment of the vitamin C 
reserves of the body; this may be due, in part at least, to the vitamin- 
splitting properties of certain intestinal strains of B. coli, as suggested 
by the work of Stepp and Schroeder (21).  A vicious circle might thus 
be formed which would lower resistance in certain individuals at cer- 
tain  times  to  a  critical point  and permit  systemic invasion of  the 
ubiquitous virus,  thus  serving to  reconcile the  constitutional pecu- 
liarities of the poliomyelitic child (22) with the epidemiological vaga- 
ries of the disease. 
There are, however, some contradictory experimental facts that must 
not be ignored.  First, we havebeen unable to obtain neutralization of 
the virus in ~itro with normal monkey brain in spite of its presumably 
high vitamin C  content  (23).  The same is true for adrenal tissue, 
although its three principal physiological constituents, i.e., adrenalin, 
coffin and ascorbic acid, in isolated form, have proved highly virucidal. 
Second, the concentration of vitamin C in the tissues is said to dimin- 
ish with the advance of age (24),  while the reverse is observed with 
respect to the neutralization phenomenon by serum.  Third, vitamin 
C-deficient guinea pigs are still refractory to poliomyelitic infection 
(25).  These questions need further elucidation as does the problem 
of how vitamin C accomplishes its apparent therapeutic effect in ex- 
perimental poliomyelitis, whether through direct action on the virus, 
or by stimulating certain enzyme systems, or by changing cell per- 
meability.  It is noteworthy that ascorbic acid, unlike immune serum, 
fails to display any preventive effect in the monkey while there are 
reasons for believing that it may be effective in therapy.  This would 
seem  to  indicate  that  the  substance  operates  only  when  actually 
s Again it should be pointed out that similar observations have been made in 
diphtheria (19) which seems to share certain aspects of its susceptibility problem 
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needed, and that vitamin C upon injection into normal, non-deficient 
animals is not retained but rapidly eliminated.  However, different 
results might be obtained in human prophylaxis, provided that further 
research reveals a  causal  relationship between disposition to infantile 
paralysis and faulty vitamin C metabolism. 
Str~M~RY AND  CO~CLVSlONS 
I.  A group of 34 monkeys were  infected intracerebrally with 0.I cc. 
of a  I0  per cent virus suspension.  Following infection, 9 animals 
were treated with daily injections of 700 to I00 rag., 16 with 50 to I0 
rag. and 9 with 5 rag. of vitamin C for a period of 2 weeks.  In the 
whole group  there were  6 animals that survived without showing any 
evidence  of paralysis.  2 of these  had received  50 to I0 rag. while 4 had 
received 5 rag.  All of 19 untreated control monkeys, infected simul- 
taneously with the same  amount of virus, developed  paralysis. 
2.  Another group of 6 monkeys  were  infected intracerebrally with 
0.05 cc. of virus.  Following  infection, one animal was treated in the 
same manner with 25  rag. and 5 with 5 mg. of vitamin C.  In the 
whole group there was one animal that survived without showing  any 
evidence of  paralysis.  This  animal had received 5 rag.  All  of  7 
untreated  control monkeys,  infected simultaneously with  the same 
amount of virus, developed  paralysis. 
3.  A third group of 22 monkeys were  infected intracerebrally with 
0.01  cc.  of virus.  Following infection, one  animal was  treated  in 
the same manner with I00 rag., 2 with 50 to I0 rag., and 19 with 5 
rag. of vitamin C.  In the whole group there were 12  animals that 
survived without showing any evidence of paralysis.  One of these 
had received 10 rag., while ii had received 5 rag.  Of 12 untreated 
control monkeys, infected simultaneously with the same amount of 
virus,  2 failed to show any paralytic symptoms  and  i0  developed 
paralysis. 
4.  A summary of the results obtained in all three groups shows:  (a) 
that  among  a  total  of  62  treated  monkeys,  19  survived  without 
paralysis and 43 succumbed to the disease, while of a total of 38 un- 
treated controls, only 2 failed to develop paralysis and 36 succumbed 
to the disease;  (b) that treatment with large doses of vitamin C was 
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to  100 rag.  developing paralysis),  that the adm{nistrafion of inter- 
mediate doses was followed by occasional survival without paralysis 
of the treated animal (3 monkeys surviving of a total of 19 which had 
received 50 to 10 rag.), and that nearly one-half of the animals which 
had received small doses escaped the disease (16 monkeys surviving 
of a total of 33 which had received 5 rag.). 
5.  Attempts to protect monkeys against subsequent intracerebral 
infection by the prophylactic administration of vitamin C, either per 
os or parenterally, have produced negative results. 
6.  The pathogenesis of infantile paralysis is discussed in the light 
of  the  experimental findings and  the possibility is  suggested that 
vitamin C represents one of the deficiency factors in the susceptibility 
problem of the human disease. 
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